On October 1, 2025, the FTSE 100 index closed at a record high of 9446 points, reflecting a 15% increase for the year. AstraZeneca's stock surged by over 11%, making it the most valuable company in London, surpassing HSBC. The rally in pharmaceutical stocks was driven by relief over the potential easing of Donald Trump's threatened tariffs on branded drugs. GSK and Hikma also saw significant gains. Despite concerns over a US government shutdown and disappointing job data, UK markets remained buoyant. The UK housing market showed signs of recovery, with house prices rising 0.5% in September. Analysts noted that AstraZeneca's dual primary listing in the US and UK could enhance its market position and investment potential.